NCT04161859

Use of Nutraceuticals in Clinical Practice

Observational Study on the Use of the Nutraceutical With Cardio-metabolic Actions in the Patient in Primary and Secondary Prevention

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 387 (actual)
• Sponsor: University of Pavia · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages.

Detailed description

The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages. In particular, attention will be focused on the following substances: berberine (500-1000 mg/day), monacolin (5-10 mg/day), phytosterols (0.9-1.8 g/day), resveratrol (100-500 mg/day), omega-3 (1-3 g/day), alpha lipoic acid (400-800 mg/day), curcumin (400 mg/day), psyllum (3.5 g/day), coenzyme Q10 (100-200 mg/day), inositol (250-600 mg/day), glucomannan (1-4 g/day), chitosan (800-1200 mg/day), guar fiber (10-20 g/day), L-arginine (250 mg/day).

Conditions

• Dyslipidemias
• Diabetes Mellitus, Type 2
• Hypertension

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nutraceutical	Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.

Timeline

• Start date: 2017-05-01
• Primary completion: 2020-12-31
• Completion: 2021-03-01
• First posted: 2019-11-13
• Last updated: 2022-05-24

Locations

1 site across 1 country: Italy